Jaguar Health Announces FDA Agreement With Clinical Trial Protocol For Full Approval Of Canalevia-CA1 For Treatment Of Chemotherapy-Induced Diarrhea In Dogs
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health announced an agreement with the FDA on a clinical trial protocol for full approval of Canalevia-CA1, a treatment for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, a canine-specific formulation of crofelemer from the Croton lechleri tree, is currently the only FDA conditionally approved treatment for this condition.

February 15, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's agreement with the FDA for a clinical trial protocol for Canalevia-CA1 represents a significant step towards full approval, potentially boosting the company's market position.
The agreement with the FDA for a clinical trial protocol is a critical regulatory milestone that could lead to full approval of Canalevia-CA1. Given its status as the only treatment for chemotherapy-induced diarrhea in dogs currently approved (even conditionally) by the FDA, this development could significantly enhance Jaguar Health's market position and investor confidence, likely leading to a positive short-term impact on JAGX's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100